Literature DB >> 32632174

Predictive factors for irreversible motor paralysis following cervical spinal cord injury.

Tsunehiko Konomi1,2, Kota Suda3, Masahiro Ozaki3,4, Satoko Matsumoto Harmon3, Miki Komatsu3, Seiji Iimoto3,5, Osahiko Tsuji3,6, Akio Minami3, Masahiko Takahata7, Norimasa Iwasaki7, Morio Matsumoto6, Masaya Nakamura6.   

Abstract

STUDY
DESIGN: A retrospective observational study.
OBJECTIVES: To elucidate predictive clinical factors associated with irreversible complete motor paralysis following traumatic cervical spinal cord injury (CSCI).
SETTING: Hokkaido Spinal Cord Injury Center, Japan.
METHODS: A consecutive series of 447 traumatic CSCI persons were eligible for this study. Individuals with complete motor paralysis at admission were selected and divided into two groups according to the motor functional outcomes at discharge. Initial findings in magnetic resonance imaging (MRI) and other clinical factors that could affect functional outcomes were compared between two groups of participants: those with and those without motor recovery below the level of injury at the time of discharge.
RESULTS: Of the 73 consecutive participants with total motor paralysis at initial examination, 28 showed some recovery of motor function, whereas 45 remained complete motor paralysis at discharge, respectively. Multivariate logistic regression analysis showed that the presence of intramedullary hemorrhage manifested as a confined low intensity changes in diffuse high-intensity area and more than 50% of cord compression on MRI were significant predictors of irreversible complete motor paralysis (odds ratio [OR]: 8.4; 95% confidence interval [CI]: 1.2-58.2 and OR: 14.4; 95% CI: 2.5-82.8, respectively).
CONCLUSION: The presence of intramedullary hemorrhage and/or severe cord compression on initial MRI were closely associated with irreversible paralysis in persons with motor complete paralysis following CSCI. Conversely, subjects with a negligible potential for recovery could be identified by referring to these negative findings.

Entities:  

Year:  2020        PMID: 32632174     DOI: 10.1038/s41393-020-0513-8

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  48 in total

1.  International standards for neurological classification of spinal cord injury (revised 2011).

Authors:  Steven C Kirshblum; Stephen P Burns; Fin Biering-Sorensen; William Donovan; Daniel E Graves; Amitabh Jha; Mark Johansen; Linda Jones; Andrei Krassioukov; M J Mulcahey; Mary Schmidt-Read; William Waring
Journal:  J Spinal Cord Med       Date:  2011-11       Impact factor: 1.985

Review 2.  Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design.

Authors:  D Lammertse; M H Tuszynski; J D Steeves; A Curt; J W Fawcett; C Rask; J F Ditunno; M G Fehlings; J D Guest; P H Ellaway; N Kleitman; A R Blight; B H Dobkin; R Grossman; H Katoh; A Privat; M Kalichman
Journal:  Spinal Cord       Date:  2006-12-19       Impact factor: 2.772

Review 3.  Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics.

Authors:  M H Tuszynski; J D Steeves; J W Fawcett; D Lammertse; M Kalichman; C Rask; A Curt; J F Ditunno; M G Fehlings; J D Guest; P H Ellaway; N Kleitman; P F Bartlett; A R Blight; V Dietz; B H Dobkin; R Grossman; A Privat
Journal:  Spinal Cord       Date:  2006-12-19       Impact factor: 2.772

4.  International Standards for Neurological and Functional Classification of Spinal Cord Injury. American Spinal Injury Association.

Authors:  F M Maynard; M B Bracken; G Creasey; J F Ditunno; W H Donovan; T B Ducker; S L Garber; R J Marino; S L Stover; C H Tator; R L Waters; J E Wilberger; W Young
Journal:  Spinal Cord       Date:  1997-05       Impact factor: 2.772

5.  Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury.

Authors:  Steven Casha; David Zygun; M Dan McGowan; Ish Bains; V Wee Yong; R John Hurlbert
Journal:  Brain       Date:  2012-04       Impact factor: 13.501

6.  A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury.

Authors:  Michael G Fehlings; Nicholas Theodore; James Harrop; Gilles Maurais; Charles Kuntz; Chris I Shaffrey; Brian K Kwon; Jens Chapman; Albert Yee; Allyson Tighe; Lisa McKerracher
Journal:  J Neurotrauma       Date:  2011-05       Impact factor: 5.269

Review 7.  Clinical diagnosis and prognosis following spinal cord injury.

Authors:  Anthony S Burns; Ralph J Marino; Adam E Flanders; Heather Flett
Journal:  Handb Clin Neurol       Date:  2012

Review 8.  Who is going to walk? A review of the factors influencing walking recovery after spinal cord injury.

Authors:  Giorgio Scivoletto; Federica Tamburella; Letizia Laurenza; Monica Torre; Marco Molinari
Journal:  Front Hum Neurosci       Date:  2014-03-13       Impact factor: 3.169

9.  Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial.

Authors:  M G Fehlings; H Nakashima; N Nagoshi; D S L Chow; R G Grossman; B Kopjar
Journal:  Spinal Cord       Date:  2015-06-23       Impact factor: 2.772

Review 10.  Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside.

Authors:  Narihito Nagoshi; Hiroaki Nakashima; Michael G Fehlings
Journal:  Molecules       Date:  2015-04-29       Impact factor: 4.411

View more
  1 in total

1.  MRI metrics at the epicenter of spinal cord injury are correlated with the stepping process in rhesus monkeys.

Authors:  Jia-Sheng Rao; Can Zhao; Shu-Sheng Bao; Ting Feng; Meng Xu
Journal:  Exp Anim       Date:  2021-11-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.